Kos Pharmaceuticals and Takeda Pharmaceuticals have reached a three-year agreement to co-promote Kos’ Niaspan and Advicor in the U.S. market. The agreement adds more than 1,000 Takeda sales representatives to the existing Kos sales force to detailthe two products developed by Kos for treating cholesterol disorders. Theincreased promotional effort is expected to significantly enhance the value ofKos’ cholesterol franchise within the U.S., the largest cholesterol market inthe world. For Takeda, the agreement fills current sales force capacity whileallowing the company to continue to grow its franchise product, Actos.
The co-promotion arrangement has a three-year termcommencing January 2004 and provides for residual payments to Takeda after thethree years, if the parties do not renew the agreement.
